LEO Pharma A/S / AstraZeneca PLC

Atopic Dermatitis

Disease Overview

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease driven by Th2-skewed immune dysregulation (IL-4, IL-13, IL-31) and epidermal barrier dysfunction, presenting as pruritic eczematous lesions. The 'Atopic Dermatitis in America' study estimated US adult prevalence at 7.3% — roughly 16.5 million adults — with ~6.6 million meeting criteria for moderate-to-severe disease.

Competitive Landscape

The biologic AD market is anchored by Sanofi/Regeneron's Dupixent (dupilumab, anti-IL-4Rα), the first-in-class biologic approved 2017 and now a multi-billion-dollar franchise across AD, asthma, CRSwNP, EoE and COPD. JAK inhibitors Rinvoq (upadacitinib, AbbVie) and Cibinqo (abrocitinib, Pfizer) compete in moderate-to-severe AD with oral convenience but boxed-warning safety constraints. LEO Pharma's tralokinumab — the asset licensed from AstraZeneca in this 2016 deal — is an anti-IL-13 monoclonal antibody approved by FDA December 2021 as Adbry (Adtralza in EU) for adults with moderate-to-severe AD; it positions as a more selective IL-13-only mechanism vs. Dupixent's dual IL-4/IL-13 blockade. Competing IL-13 entrants include Eli Lilly's lebrikizumab (Ebglyss, approved 2024). Per AstraZeneca's IR press release (astrazeneca.com 2016-07-01) and the GEN Engineering News deal coverage (genengnews.com 2016-07-01), LEO paid $115M upfront plus up to $1B in commercial milestones and mid-teen tiered royalties on tralokinumab — and also took European rights to brodalumab. BioPharma Dive characterized the deal as part of AstraZeneca's deliberate out-licensing strategy to refocus on oncology while letting LEO build its dermatology biologics franchise (biopharmadive.com 2016-07-01). Brodalumab (later marketed as Kyntheum/Siliq) launched in psoriasis but underperformed commercially due to a black-box suicidal-ideation warning.